Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support

MT Newswires Live03-27

Sanofi (SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.

The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.

A final decision from regulators is expected in the coming months, Sanofi said.

Shares of Sanofi were up 2% pre-bell Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622295821?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622295821","market":"us","top_or_hot":-1,"title":"Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.</p><p>The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.</p><p>A final decision from regulators is expected in the coming months, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said.</p><p>Shares of Sanofi were up 2% pre-bell Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-27 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.</p><p>The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.</p><p>A final decision from regulators is expected in the coming months, <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> said.</p><p>Shares of Sanofi were up 2% pre-bell Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4156","symbol_name":"煤与消费用燃料","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2622295821","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622295821","pubTimestamp":1774615975,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.A final decision from regulators is expected in the coming months, Sanofi said.Shares of Sanofi were up 2% pre-bell Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4156":"煤与消费用燃料","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SNYNF":"Sanofi","BK4007":"制药","SNY":"赛诺菲安万特"},"translate_title":"赛诺菲表示皮下注射治疗多发性骨髓瘤的Sarclisa赢得了欧盟小组的支持","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1,"SNYNF":1.5},"content_text":"Sanofi (SNY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma.The company said the recommendation covers use of the subcutaneous form across all indications currently approved for the intravenous formulation in the European Union, and is based on late-stage trial data showing that the subcutaneous version performed comparably to the intravenous form, supported by several additional studies.A final decision from regulators is expected in the coming months, Sanofi said.Shares of Sanofi were up 2% pre-bell Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622295821","isCrawlerRequest":true}